Cargando…

An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma

Objective: To determine the efficacy of pembrolizumab relative to other treatments used in stage III melanoma by conducting a systematic literature review (SLR) and network meta-analysis (NMA). Methods: A SLR was conducted to identify randomized clinical trials (RCTs) evaluating approved adjuvant tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzi, Maria, Arndorfer, Stella, Aguiar-Ibañez, Raquel, Scherrer, Emilie, Liu, Frank Xiaoqing, Krepler, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713115/ https://www.ncbi.nlm.nih.gov/pubmed/31489255 http://dx.doi.org/10.1080/21556660.2019.1649266

Ejemplares similares

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
por: Bensimon, Arielle G., et al.
Publicado: (2020)

Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021)

Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis
por: Cowey, Charles Lance, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
por: Zhang, Shujing, et al.
Publicado: (2023)

Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients
por: Aguiar-Ibáñez, Raquel, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting
por: Cowey, Charles L., et al.
Publicado: (2020)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article)
por: Cowey, C. Lance, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection
por: Lopez-Vinueza, Cesar, et al.
Publicado: (2023)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
por: Läubli, Heinz, et al.
Publicado: (2015)

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report
por: Kuint, R., et al.
Publicado: (2017)

Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma
por: Zheng, Yixuan James, et al.
Publicado: (2018)

RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
por: Siddiqui, Jalal, et al.
Publicado: (2021)

Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
por: Kang, S, et al.
Publicado: (2023)

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
por: Eggermont, Alexander M. M., et al.
Publicado: (2020)

A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
por: Qiao, Nan, et al.
Publicado: (2021)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study
por: Liu, Frank Xiaoqing, et al.
Publicado: (2019)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab treatment for metastatic melanoma
por: Mutgi, Krishna A.J., et al.
Publicado: (2016)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
por: Quinn, Casey, et al.
Publicado: (2016)

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
por: Rosner, Samuel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_coil5ddgu6bgtsrul7jv2e0tmf